Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $10.6552W HIGH $19.05
Volume
4.70 M
Value Traded
21.05 M
Short % Float
50.04%
-3.86%Week
-15.52%1 Month
+28.84%3 Month
+48.9%6 Month
-35.84%5 Year
-35.84%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.54 B
EPS (TTM)
-1.12
P/E Ratio
-
Ent. Value
5.34 B
Total Shares
281.35 M
Float Shares
27.17 M
Insiders
90.34%
Institutions
13.26%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MMED Catalyst Timeline
Dated clinical, regulatory and corporate events for MiniMed Group, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for MiniMed Group, Inc.
5Total events
2Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 2
TBD
T3Corporate Approval
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 3
●Management ChangeCorporate
MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
●Corporate ApprovalCorporate
MiniMed files Form S-4 registration statement for Medtronic exchange offer
Past FDA Catalysts and PDUFA Decisions
How MMED actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F17 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 97%
Small Cap(rank 638 of 658)
Percentile Rank
MiniMed Group, Inc. has significant pipeline risk (17/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every MMED program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| MiniMed™ 780G system | type 1 diabetes | 2026-05-21 | Instinct: Time in Range 79.1 %, Hb A1c 6.7 %, Mean Sensor Glucose 137.9 mg/dL, Time in Auto Mode 90.0 %; Simplera Sync: Time in Range 80.6 %, Hb A1c 6.8 %, Mean Sensor Glucose 139.5 mg/dL, Time in Auto Mode 92.6 %Read More | New Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G SystemRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wills Courtney NelsonOfficer (SVP, Gen. Counsel, Corp. Sec.) | Grant/Award | 60,730 116,089 held | $0.00 | 07/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MMED
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.5 % | 4.73 M | 317.32 K |
MMED Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MMED ranks across every disease it competes in
Competitive Position is a premium feature
See how MMED ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMMED News
MMED▲ +0.5%today
Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes
A recent six-month randomized trial demonstrated that individuals with type 1 diabetes using the MiniMed Smart MDI system who responded more frequently to alerts had improved glucose outcomes. Specifically, higher responders experienced an average of 8.1 percentage points more Time in Range and a 0.6 percentage point reduction in HbA1c. The findings were presented at the European Association for the Study of Diabetes meeting.
Read more →MMEDMiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
MiniMed has appointed Sheila Denton as General Counsel and Corporate Secretary. Denton, who has over 25 years of experience in the pharmaceutical and biotech sectors, will support the company's growth as it operates as an independent public entity. She succeeds Courtney Nelson Wills and is expected to enhance MiniMed's strategic direction.
Read more →MMEDMiniMed Files Form S-4 Registration Statement in Connection with Medtronic Exchange Offer Announcement
MiniMed has filed a Form S-4 Registration Statement with the SEC as part of Medtronic's exchange offer for MiniMed shares. Medtronic aims to exchange up to 225 million shares of MiniMed common stock for its ordinary shares. This move marks the final stage of MiniMed's separation from Medtronic, allowing for greater autonomy in operations.
Read more →MMED▲ +10.7%on this news
MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
MiniMed reported a strong start to fiscal year 2027 with net sales of $843 million, reflecting a 17% increase. The company experienced accelerated U.S. growth of 13% and robust international growth of 18%. MiniMed's innovation pipeline is ahead of schedule, with significant advancements including FDA submissions and new product launches. The company has raised its organic revenue growth guidance for the fiscal year.
Read more →MMED▼ -5.1%on this news
MiniMed to Participate in Upcoming Investor Conferences
MiniMed (Nasdaq: MMED) will participate in upcoming investor conferences, including the 21st Annual Wells Fargo Healthcare Conference and the Bank of America Global Healthcare Conference. CEO Que Dallara and CFO Chad Spooner will represent the company, discussing its advancements in diabetes technology. Live webcasts will be available on the MiniMed Investor Relations website.
Read more →MMEDMiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor
MiniMed has begun shipping its MiniMed Flex™ insulin pump in the U.S., featuring the Instinct sensor from Abbott. This innovative system is the smallest app-controlled insulin pump available, designed to improve diabetes management. Users can enjoy the convenience of up to 15 days of continuous sensor wear.
Read more →MMEDMiniMed Flex™ Now Available to Medicare and Medicare Advantage Beneficiaries
MiniMed has announced that its MiniMed Flex™ insulin pump system is now available to Medicare and Medicare Advantage beneficiaries. This compact, app-controlled device is designed to simplify diabetes management and improve quality of life. The system utilizes SmartGuard™ technology, which automatically adjusts insulin delivery, and has shown positive outcomes in previous studies. The availability of this technology is expected to benefit more individuals living with diabetes.
Read more →MMEDMiniMed to Announce Its Fiscal Year 2027 First Quarter Financial Results
MiniMed (Nasdaq: MMED) announced its upcoming financial results for the first quarter of fiscal year 2027, set to be released on September 1, 2026. The results will be accompanied by a webcast discussion, providing insights into the company's performance. MiniMed continues to innovate in diabetes technology, enhancing the lives of those managing diabetes.
Read more →MMEDMiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors
MiniMed has appointed David Endicott, CEO of Alcon, and Linnea Burman to its Board of Directors, expanding the board from nine to eleven members. Endicott's experience in scaling healthcare businesses will be valuable as MiniMed continues its journey as an independent company. Burman, from Medtronic, adds further expertise to the board.
Read more →MMEDMiniMed introduceert Instinct-sensoren in Europa en biedt mensen met diabetes meer keuze met dezelfde bewezen resultaten
MiniMed has announced the commercial launch of its MiniMed 780G system integrated with Abbott's Instinct sensor in Europe. This system, along with the MiniMed Go system featuring the Instinct Go sensor, aims to provide enhanced diabetes management options. The rollout of these sensors marks a significant expansion of MiniMed's offerings in the European market.
Read more →MMEDMiniMed launches Instinct sensors in Europe giving people with diabetes more sensor choice with the same proven outcomes
MiniMed has launched the Instinct and Instinct Go sensors in Europe, integrating them with its MiniMed 780G and MiniMed Go systems. This expansion provides users with more choices for diabetes management while maintaining proven outcomes. The rollout will occur gradually, enhancing MiniMed's sensor offerings in the region.
Read more →MMEDMiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.
MiniMed has launched its smallest insulin pump, the MiniMed Flex™, in the U.S. This app-controlled device is designed for individuals with type 1 or insulin-requiring type 2 diabetes. It comes with the Simplera Sync™ sensor, which features a simple two-step insertion process. An additional launch with Abbott's Instinct sensor is expected later this summer.
Read more →MMED▲ +15.9%on this news
MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results Provides Fiscal Year 2027 Outlook Continued momentum in Q4, with net sales of $837 million growing 16%
MiniMed reported strong financial results for the fourth quarter and full year of fiscal 2026, with net sales reaching $837 million, representing a 16% increase. For the first time, the company's annual net sales surpassed $3 billion, with a 14% overall growth. Positive market response is driven by the adoption of the MiniMed 780G system and successful product launches, including MiniMed Flex and MiniMed Go. Looking ahead, MiniMed projects approximately 10% organic revenue growth for fiscal year 2027, supported by new product offerings and expansion in both U.S. and international markets.
Read more →MMED▲ +15.9%on this news
MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott
MiniMed has announced an expanded agreement with Abbott to develop dual glucose-ketone sensors that will integrate with MiniMed's smart dosing systems. This collaboration aims to enhance diabetes management by enabling early detection of rising ketones, which can help prevent diabetic ketoacidosis (DKA). The sensors are designed to be the same size as the existing Instinct sensor and will provide users with additional safety features. Regulatory updates and commercialization details are expected in the coming months.
Read more →MMEDMiniMed to Showcase MiniMed Flex™ and MiniMed Go™ at the American Diabetes Association Scientific Sessions
MiniMed will showcase its latest diabetes technology, including the MiniMed Flex™ and MiniMed Go™, at the American Diabetes Association Scientific Sessions in New Orleans from June 5-8. This event marks MiniMed's first major presence as a standalone public company. Attendees will have opportunities for hands-on demonstrations and will learn about new clinical data supporting the effectiveness of these technologies.
Read more →MMED▼ -5.8%on this newsshared move
MiniMed to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
MiniMed will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The management will engage in a fireside chat, which will be accessible via a live webcast. MiniMed continues to innovate in diabetes technology, providing comprehensive solutions for diabetes management.
Read more →MMEDNew Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G System
A new randomized crossover study has shown that glycemic outcomes for participants using the MiniMed™ 780G system are nearly identical with both the Simplera Sync™ and Instinct sensors. The study emphasizes the importance of the SmartGuard™ algorithm in driving these outcomes. No adverse events were reported, reinforcing the system's reliability in managing diabetes.
Read more →MMED▲ +5.7%on this news
MiniMed to announce financial results for its fourth quarter and full fiscal year 2026
MiniMed (Nasdaq: MMED) will announce its financial results for Q4 and full fiscal year 2026 on June 3, 2026. A news release will be issued at 3:45 a.m. PDT, followed by a webcast at 5:45 a.m. PDT to discuss the results. The company continues to lead in diabetes technology, providing integrated solutions for diabetes management.
Read more →MMEDMiniMed announces closing of Initial Public Offering NORTHRIDGE, CA
MiniMed Group, Inc. announced the successful closing of its initial public offering of 28 million shares at $20 each, raising about $538 million. The IPO marks a significant milestone for the company, which remains approximately 90% owned by Medtronic. MiniMed plans to utilize the proceeds for corporate purposes and to settle intercompany debt. The offering involved several major financial institutions as bookrunners and managers, but the company faces uncertainties that could affect its future performance.
Read more →About MiniMed Group, Inc.
Headquarters18000 DEVONSHIRE ST., NORTHRIDGE, CA, 91325
BIOPHARMAWATCH ELITE PLUS
Trade the next MMED catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime